{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:25:51Z","timestamp":1777883151879,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rceng.2026.502520","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:03:18Z","timestamp":1774972998000},"page":"502520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone in heart failure with ejection fraction \u226540%: state of the art and future perspectives"],"prefix":"10.1016","volume":"226","author":[{"given":"Pau","family":"Ll\u00e0cer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Cobo Marcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M.","family":"Perez Belmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"P\u00e9rez Silvestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sanchez Marteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Comin Colet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0005","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 Heart Disease and Stroke Statistics: a report of US and Global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.rceng.2026.502520_bib0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.rceng.2026.502520_bib0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","article-title":"Epidemiolog\u00eda y tratamiento de la insuficiencia cardiaca en Espa\u00f1a: estudio PATHWAYS-HF","volume":"75","author":"Sicras-Mainar","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"17","key":"10.1016\/j.rceng.2026.502520_bib0025","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.3390\/jcm11175199","article-title":"Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"11","author":"Escobar","year":"2022","journal-title":"J Clin Med"},{"issue":"36","key":"10.1016\/j.rceng.2026.502520_bib0030","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.rceng.2026.502520_bib0040","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.rceng.2026.502520_bib0045","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.medcli.2020.10.022","article-title":"Causes of death in hospitalized patients in internal medicine departments with heart failure according to ejection fraction. RICA registry","volume":"158","author":"Guisado-Espartero","year":"2022","journal-title":"Med Clin (Barc)"},{"issue":"10","key":"10.1016\/j.rceng.2026.502520_bib0060","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jchf.2021.05.009","article-title":"Advanced heart failure epidemiology and outcomes: a population-based study","volume":"9","author":"Dunlay","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.rceng.2026.502520_bib0065","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.rceng.2026.502520_bib0070","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"37","key":"10.1016\/j.rceng.2026.502520_bib0075","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.rceng.2026.502520_bib0080","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.rceng.2026.502520_bib0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0090","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"31","key":"10.1016\/j.rceng.2026.502520_bib0095","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0100","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0105","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.rceng.2026.502520_bib0110","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14740338.2022.2130889","article-title":"Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective","volume":"21","author":"Marzolla","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.rceng.2026.502520_bib0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.rceng.2026.502520_bib0120","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s11886-023-01998-0","article-title":"Cardiovascular and renal benefit of novel non-steroidal mineralocorticoid antagonists in patients with diabetes","volume":"25","author":"Kintscher","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"10.1016\/j.rceng.2026.502520_bib0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nefroe.2023.09.002","article-title":"Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease","volume":"43","author":"G\u00f3rriz","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.rceng.2026.502520_bib0130","unstructured":"Finerenona. Ficha t\u00e9cnica. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230206158345\/anx_158345_es.pdf."},{"issue":"9","key":"10.1016\/j.rceng.2026.502520_bib0135","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4S","key":"10.1016\/j.rceng.2026.502520_bib0140","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"24","key":"10.1016\/j.rceng.2026.502520_bib0145","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.rceng.2026.502520_bib0150","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.rceng.2026.502520_bib0160","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.rceng.2026.502520_bib0165","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rceng.2026.502520_bib0170","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"1 Suppl 1","key":"10.1016\/j.rceng.2026.502520_bib0175","first-page":"S239","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12882-024-03652-5","article-title":"Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes","volume":"25","author":"Khan","year":"2024","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.rceng.2026.502520_bib0185","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/joim.20050","article-title":"Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes","volume":"297","author":"Zannad","year":"2025","journal-title":"J Intern Med"},{"issue":"16","key":"10.1016\/j.rceng.2026.502520_bib0190","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamacardio.2024.3782","article-title":"Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Vaduganathan","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.rceng.2026.502520_bib0200","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0205","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamacardio.2025.1775","article-title":"Finerenone according to frailty in heart failure: a prespecified analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Butt","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2024.4613","article-title":"Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rceng.2026.502520_bib0215","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70034","article-title":"Finerenone according to insulin resistance in heart failure: insights from the FINEARTS-HF trial","author":"Ostrominski","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.rceng.2026.502520_bib0220","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.3649","article-title":"Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0235","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2026.502520_bib0240","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70052","article-title":"Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: findings from FINEARTS-HF","author":"Ferreira","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2026.502520_bib0245","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70034","article-title":"Finerenone across the spectrum of kidney risk in heart failure: the FINEARTS-HF trial","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0255","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2026.502520_bib0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.rceng.2026.502520_bib0270","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0275","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ejhf.3694","article-title":"Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"27","author":"Cunningham","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2026.502520_bib0280","article-title":"Effects of finerenone on readmissions for heart failure: insights from the FINEARTS-HF trial","author":"Bhatt","year":"2025","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0285","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ejhf.3669","article-title":"The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of FINEARTS-HF","volume":"27","author":"Kondo","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.rceng.2026.502520_bib0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2025.0016","article-title":"Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Cunningham","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0295","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.rceng.2026.502520_bib0300","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamacardio.2025.2551","article-title":"Efficacy and tolerability of finerenone according to the use and dosage of diuretics: a prespecified analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.rceng.2026.502520_bib0305","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamacardio.2025.0848","article-title":"Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Matsumoto","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rceng.2026.502520_bib0310","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3682","article-title":"Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","author":"Chimura","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0315","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ejhf.3661","article-title":"Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2026.502520_bib0320","article-title":"Finerenone and New York Heart Association functional class in heart failure: the FINEARTS-HF trial","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.rceng.2026.502520_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2024.10.020","article-title":"Finerenone and Quality of life assessed using the EuroQol 5-Dimension Questionnaire Level-Sum-Score in patients with heart failure and mildly reduced or preserved ejection fraction","author":"Yang","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.rceng.2026.502520_bib0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.rceng.2026.502520_bib0335","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.rceng.2026.502520_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.08.039","article-title":"Anthropometric measures, cardiovascular outcomes, and treatment effects of finerenone in cardiovascular-kidney-metabolic disease: pooled participant-level analysis of 3 global trials","author":"Ostrominski","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.rceng.2026.502520_bib0345","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone Reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis","volume":"85","author":"Pabon","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.rceng.2026.502520_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-heart analysis","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.rceng.2026.502520_bib0355","article-title":"Effect of finerenone on morbidity and mortality in CKD","author":"Ostrominski","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"9386","key":"10.1016\/j.rceng.2026.502520_bib0360","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.rceng.2026.502520_bib0365","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.rceng.2026.502520_bib0370","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.rceng.2026.502520_bib0375","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.rceng.2026.502520_bib0380","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502520_bib0385","unstructured":"Bayer AG. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06024746, accessed Oct 2025."},{"key":"10.1016\/j.rceng.2026.502520_bib0390","unstructured":"Bayer AG. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06008197, accessed Oct 2025."},{"key":"10.1016\/j.rceng.2026.502520_bib0395","unstructured":"AstraZeneca. Study to Evaluate the Effect of Balcinrenone\/\u200bDapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06307652, accessed Oct 2025."},{"key":"10.1016\/j.rceng.2026.502520_bib0400","unstructured":"Uppsala University. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02901184, accessed Oct 2025."},{"key":"10.1016\/j.rceng.2026.502520_bib0405","unstructured":"Charite University, Berlin, Germany. Spironolactone in the Treatment of Heart Failure (SPIRIT-HF). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04727073, accessed Oct 2025."},{"key":"10.1016\/j.rceng.2026.502520_bib0410","unstructured":"Boehringer Ingelheim. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06424288, accessed Oct 2025."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:35:38Z","timestamp":1777599338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887426000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2254887426000731"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502520","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone in heart failure with ejection fraction \u226540%: state of the art and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2026.502520","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502520"}}